Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares

By Yahoo! Finance | Nov 21, 2024 at 06:17 AM EST

Amgen's MariTide weight-loss drug is being compared to popular GLP-1 drugs. Analysts are eager for Phase 2 trial results expected to show at least 20% weight loss with fewer side effects, potentially revolutionizing the obesity drug market.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.